Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 23,800 shares, a growth of 28.0% from the August 15th total of 18,600 shares. Based on an average daily volume of 2,060,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are sold short.
Shares of NYSEAMERICAN SYN opened at $0.46 on Wednesday. Synthetic Biologics has a twelve month low of $0.26 and a twelve month high of $1.70. The company has a 50 day moving average price of $0.37. The stock has a market capitalization of $60.74 million, a PE ratio of -1.07 and a beta of 1.85.
Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01.
A number of institutional investors have recently bought and sold shares of SYN. tru Independence LLC acquired a new position in Synthetic Biologics during the 1st quarter worth approximately $30,000. Blair William & Co. IL increased its holdings in shares of Synthetic Biologics by 142.0% in the 2nd quarter. Blair William & Co. IL now owns 171,301 shares of the company’s stock valued at $103,000 after acquiring an additional 100,508 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Synthetic Biologics by 1,706.7% in the 1st quarter. Northern Trust Corp now owns 246,542 shares of the company’s stock valued at $168,000 after acquiring an additional 232,896 shares during the last quarter. Virtu Financial LLC grew its stake in Synthetic Biologics by 347.1% during the 1st quarter. Virtu Financial LLC now owns 466,704 shares of the company’s stock worth $318,000 after buying an additional 362,319 shares during the last quarter. Finally, State Street Corp acquired a new position in Synthetic Biologics during the 2nd quarter worth $284,000. Hedge funds and other institutional investors own 5.09% of the company’s stock.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation.
Read More: What are the FAANG Stocks?
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.